The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
04-Feb-25
Pending
$1.1 billion
Target:
PRISM Vision Group
Acquiror:
McKesson Corporation
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
13-Nov-24
Pending
Undisclosed
Target:
Centogene GmbH
Acquiror:
Charme Capital Partners
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
01-Feb-22
Undisclosed
Target:
Alteon Health
Acquiror:
U.S. Acute Care Solutions
Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions
28-Jan-22
Undisclosed
Target:
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Acquiror:
Laboratoires Théa SAS
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
07-Dec-21
$153 million
Target:
Japan Medical Dynamic Marketing
Acquiror:
Mitsui Chemicals
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
29-Sep-21
~$1.1 billion
Target:
Procaps Group
Acquiror:
Union Acquisition Corp. II (NASDAQ: LATN)
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
20-Sep-21
Undisclosed
Target:
Faes Farma, flagship product Bilastine
Acquiror:
Hikma Specialty USA INC
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
30-Jun-21
Pending
Undisclosed
Target:
Deltalab
Acquiror:
SCG Packaging Public Company Limited
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
26-Feb-21
$2.0 billion
Target:
MDLIVE
Acquiror:
Cigna
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization